Effectiveness Or Bust: Without Benefit, No Case For Keeping Makena On The Market, CDER Says

FDA Center for Drug Evaluation and Research officials say accelerated approval of Covis’ preterm birth prevention drug should be withdrawn because substantial evidence of effectiveness no longer exists – separate from any concerns about study feasibility, off-label use or compounding.

Makena hearing and driving risks
FDA's Christine Nguyen aimed to center efficacy in the discussion by noting that everything involves risks, and people wouldn't drive cars unless it got them somewhere. • Source: Shutterstock

At the first day of the Makena public hearing on 17 October, the US FDA’s Center for Drug Evaluation and Research sought to focus attention on the key reason for its proposal to withdraw Covis Pharma’s preterm birth prevention drug – a lack of substantial evidence of effectiveness – without getting bogged down in ancillary issues such as study feasibility, off-label prescribing and compounding.

By placing effectiveness at the heart of their argument for withdrawal, CDER officials suggested that no case can be made...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards